Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Product ID

Click to order products descending

Display 45 Products per page

Colorectal Cancer KOL Interview – UK

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Colorectal Cancer KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Interventional Neurology: Mechanical Thrombectomy Devices

$4,750.00

Mechanical thrombectomy (MT) is an emergency surgical technique used in eligible patients experiencing acute ischemic stroke (AIS) to remove a blood clot in the brain. In 2021, the combined global market for neuroendovascular MT devices was estimated at approximately $706m.
June 14, 2022
Find out more
Melanoma KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.
February 25, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.
April 21, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

$599.00

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

$599.00

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – UK

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – Italy

$599.00

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.
March 14, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – US, South

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Prostate Cancer KOL Interview – UK #2

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.
February 9, 2022
Find out more
Prostate Cancer KOL Interview – UK #1

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.
February 9, 2022
Find out more
Prostate Cancer KOL Interview – US, Northeast #2

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.
February 9, 2022
Find out more
Prostate Cancer KOL Interview – US, Northeast #1

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.
February 9, 2022
Find out more
Atopic Dermatitis and Psoriasis KOL Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
Drug Delivery: Injection Devices

$4,750.00

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn.
March 15, 2022
Find out more
Bone Grafts and Substitutes

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for bone grafts and substitutes. Product segments covered by this report include allografts and synthetic bone substitutes, growth factors, and cellular bone matrices.
February 15, 2022
Find out more
Atopic Dermatitis and Psoriasis KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.
November 18, 2021
Find out more
Biomedtracker Meddevice Tracker Early 2022 Outlook Report

$4,750.00

Biomedtracker Meddevice Tracker Early 2022 Outlook Report
February 8, 2022
Find out more
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.
December 22, 2021
Find out more
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.
December 22, 2021
Find out more
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.
December 22, 2021
Find out more
Digital Health Technology and Regulatory Overview

$4,750.00

This technology report provides an overview of the current landscape for digital health devices and software. This includes a summary of regulation and reimbursement policies and highlights of major product categories.
December 13, 2021
Find out more
Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and AVM embolization systems. This market comprises the following product segments: endovascular coils, liquid embolics, stents for stent-assisted coiling, flow diversion and flow disruption systems, and other novel/emerging embolization devices. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets. The forecast range for this report is 2020–25.
December 16, 2021
Find out more
Interventional Cardiology: Implantable Cardioverter Defibrillators

$4,750.00

The ICD market alone lost nearly $1bn from $8.3bn in 2019 to $7.4bn in 2020 due to a combination of lockdowns, supply chain disruptions, and logistical strain in the healthcare space. The global market for ICD devices, along with many other medical devices, is currently recovering from a major economic downturn. Therefore, to provide context as to the nature of this market recovery and what exactly it is recovering from, data from 2019 are included. Types of cardiac defibrillators covered by the scope of this report include ICDs, subcutaneous ICDs (S-ICDs), and cardiac resynchronization therapy defibrillators (CRT-Ds). The regions covered by this report are the US, the 5 major European economies (UK, France, Spain, Italy, Germany), Japan, and the rest of the world. The forecast range is 2020-2025.
December 21, 2021
Find out more
Drug Delivery: Inhalation Devices

$4,750.00

This Meddevicetracker report includes a discussion of inhalation devices, products, current/forecast markets, competitors, and opportunities in the global markets for inhalation-based drug delivery devices for the treatment of asthma and COPD and much more.
December 14, 2021
Find out more
Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration – 2021

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Geographic markets covered by this analysis comprise the US, Japan, five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW), which includes all other countries.
November 2, 2021
Find out more
Liquid Biopsy Oncology Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of liquid biopsy products used in the field of oncology. In 2020, the global market for liquid biopsy products for oncology applications was valued at approximately $1.9bn.
October 11, 2021
Find out more
Disease Analysis: Diffuse Large B-Cell Lymphoma (DLBCL)
Read More
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which originates in the lymphatic system when B lymphocytes become enlarged and proliferate uncontrollably to form a tumor mass. DLBCL can arise de novo or as a progression or transformation from more indolent disease such as chronic lymphocytic leukemia (in which case it is also known as Richter’s transformation) or follicular lymphoma (FL).
April 21, 2022
Find out more
Interventional Cardiology: Carotid Artery Stents and Embolic Protection Systems

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for carotid artery stents and embolic protection systems. Geographically
September 9, 2021
Find out more
Follicular Lymphoma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.
June 11, 2021
Find out more
Transcatheter Heart Valve Repair and Replacement Devices

$4,750.00

In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales.
August 30, 2021
Find out more
Q3 2021 Outlook Report

$4,750.00

In this report, we cover catalysts from 27 drugs, devices, diagnostics, and deals expected to occur in the third quarter of 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.
June 2, 2021
Find out more
HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.
August 10, 2021
Find out more
HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HIV PrEP. Drug pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include islatravir and cabotegravir.
August 10, 2021
Find out more
Chronic Myeloid Leukemia (CML) KOL Interview – US, Midwest

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic myeloid leukemia. Disease stratifications by phase, as well as unmet needs, are also discussed. Key pipeline assets highlighted include asciminib, SCO-088, and ASTX030.
August 5, 2021
Find out more
Chronic Myeloid Leukemia (CML) KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for chronic myeloid leukemia. Disease stratifications by phase, as well as unmet needs, are also discussed. Key pipeline assets highlighted include asciminib, SCO-088, and ASTX030.
August 5, 2021
Find out more
Fracture Fixation Devices Market

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for fracture fixation devices.
August 5, 2021
Find out more
Follicular Lymphoma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression, as well as unmet needs, are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, and mosunetuzumab.
July 16, 2021
Find out more
Point of Care Diagnostics

$4,750.00

Point of care in vitro diagnostics is being applied to an increasingly wide range of applications in infectious disease, cardiovascular, respiratory, and metabolic disease diagnosis and screening. The market is undergoing rapid expansion, primarily due to the demand for COVID-19 testing; however, other product segments will also contribute to market growth during the forecast period.
June 28, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *